Here’s the final version of the first paper from our lab. Standard therapies used to treat prostate cancer regulate glyco-immune checkpoints. We’re doing a lot more on this so watch this space!
https://t.co/bIGDWqZrxz
@ProstateUKProfs@nubiosciences@NU_Cancer#glycotime
Interested in doing a PhD in tumour immunology? We’re looking for a keen and enthusiastic student to join our group!
https://t.co/6dC9gJSzZ8
📧 Please get in touch if you’d like to chat further ([email protected])
Coming soon! 📢
Applications for our Career Acceleration Fellowships open in March.
We’re offering up to £350K over 3-4 years to support early career prostate cancer researchers to advance their career and build collaborations.
🚨Find out more here: https://t.co/8wGTrWw4ik
I have previously attended these brilliant events for ECR’s and can’t emphasise enough how valuable they have been. A great way to keep up with the latest research, get some additional training and meet new collaborators!
📣 We're excited Making Progress, our event for Early Career Researchers, will be back in 2025.
📆 Save the date and look out for updates including how to register for the event that will help you become the next leader in the field.
📙 Read more: https://t.co/9HjaRunvYi
Very happy to share my thoughts about the importance of allyship with @CRUKresearch. Thanks to everyone involved in our EDI @CRUK_SI who helped me shape my thoughts!
https://t.co/3JsEZ52StZ
A comprehensive discussion about methods of detection of anti-Neu5Gc antibodies by brilliant @DiMeN_DTP student @eshutton1. It’s a joy to be involved with this project led by such a talented student @UniOfYork@nubiosciences. Congrats Esme!
Started life as a spreadsheet of experiment conditions to try, ended up as the first paper of my PhD- see below for the review I wrote about strategies to detect anti-Neu5Gc antibodies in humans!
https://t.co/NZLrRoEnmq
Meet @BrettGarabedian#ARCSScholar@scrippsresearch who uses chemistry & protein engineering to empower our immune system against diseases, including chronic infection & cancer. Join us April 27 (4-8 pm) at our SOY event to honor our Scholars! More info:
https://t.co/yIfJ6RJHul
📢 What role do therapies targeting glyco-immune checkpoints have in #prostatecancer?
Dr Emma Scott and colleagues at @NU_Cancer and beyond show ST3Gal1 is critical to anti-tumour immunity. Congratulations publishing in @CommsBio
Grab a ☕and read now: https://t.co/g4Fa79LH2k
Here’s the final version of the first paper from our lab. Standard therapies used to treat prostate cancer regulate glyco-immune checkpoints. We’re doing a lot more on this so watch this space!
https://t.co/bIGDWqZrxz
@ProstateUKProfs@nubiosciences@NU_Cancer#glycotime